Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Verve Therapeutics, Inc. (VERV)
Company Research
Source: Yahoo! Finance
All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 111%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Looking ahead, revenue is expected to decline by 16% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 21%. Performance of the American Biotechs industry. The company's shares are up 6.5% from a week ago. Be aware that Verve Therapeutics is showing 4 warning signs in our investment analysis and 1 of those is a bit unpleasant... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommend
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Investors to Inquire about Securities InvestigationAccesswire
- Verve Therapeutics Slides As Insider Purchases Lose Another US$65k [Yahoo! Finance]Yahoo! Finance
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Verve Therapeutics, Inc. (VERV) And Encourages Investors to Reach OutAccesswire
- VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the FirmAccesswire
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
VERV
Earnings
- 11/5/24 - Beat
VERV
Sec Filings
- 12/4/24 - Form 4
- 12/3/24 - Form 4
- 11/18/24 - Form SC
- VERV's page on the SEC website